Olympus Corporation of Asia Pacific (APAC) has announced a milestone for its iTind device with expanded availability across major markets in the APAC region, a move in line with its commitment and purpose of making people’s lives healthier, safer and more fulfilling.
Already marketed in the United States and Europe, the iTind procedure is a minimally invasive solution for the treatment of benign prostatic hyperplasia (BPH), also known as an enlarged prostate. With a launch in Korea scheduled in March, iTind will become available in six markets across APAC.
“With our upcoming launch in Korea, achieving wider availability of the iTind device in APAC is an important milestone for physicians and patients in our region. We’re excited to provide increased access to a minimally invasive outpatient BPH procedure for suitable patients, addressing a common health problem for men over 50 with the risk of BPH increasing with age. Symptoms of BPH include frequent urination with a sense of urgency and a weak urinary stream and excessive urination at night. The iTind procedure provides a rapid and effective patient-focused treatment option, with the added benefit of the procedure being able to be performed in a clinic room under local anaesthesia, helping ease pressure on hospital capacity.” said Daisuke Goto, Head of Surgical Business at Olympus APAC.
As part of the roll-out of the iTind device across the region, Japan-headquartered Olympus has designed a comprehensive training programme to support physicians and to maximise the success of incorporating the iTind procedure as part of their clinical practice.
